Biotech Business - December 3, 2021
Ultimovacs granted Orphan Drug Designation by FDA
Ultimovacs has announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma. UV1, as add-on therapy to checkpoint inhibitors ipilimumab and nivolumab, is currently being studied as first-line treatment for metastatic melanoma in a Phase […]
Collaboration - November 30, 2021
Immunicum and PCI Biotech extend their collaboration
Immunicum and PCI Biotech Holding have announced an extension of their current research collaboration to explore novel cancer vaccination treatments. The companies jointly research the possibility to overcome current hurdles in cancer immunotherapy by introducing tumor independent immune targets into the tumor microenvironment, in combination with vaccination or adoptive immunotherapies. The so-called Tumor Independent Antigen […]
Agreement - November 23, 2021
Vaccibody becomes Nykode and enters agreement worth 900 MUSD
The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license and collaboration agreement with Regeneron includes five distinct programs, three within cancer and two within infectious diseases. Each of these may include several vaccine candidates, […]
COVID-19 - October 18, 2021
Norwegian nasal drug delivery receives award
Scientist and company founder Per Gisle Djupesland’s invention could be used to treat symptoms and transmission of COVID-19. Targeted drug delivery is critical when treating chronic inflammatory nasal and sinus diseases. Medicine could be deposited in the wrong areas, swallowed or passed straight through the nasal passages into the lungs, and traditional spray pumps cannot […]
Financing - September 17, 2021
NordicRWE granted 16 million NOK
The Research Council of Norway recently awarded a grant to the new company NordicRWE. NordicRWE was granted 16 million NOK for their research and development (R&D) project that will focus on applying Real-World Evidence (RWE) in different steps in the drug development process, reports Oslo Cancer Cluster. The vision of NordicRWE The vision of NordicRWE […]
In a new job - September 10, 2021
BerGenBio announces leadership changes
BerGenBio has announced the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the company with immediate effect to pursue other business interests. “I have thoroughly enjoyed my past twelve years at BerGenBio and […]
